<DOC>
	<DOCNO>NCT00965224</DOCNO>
	<brief_summary>Dendritic cell therapy promise strategy adjuvant cancer therapy set minimal residual disease ( MRD ) fight cancer relapse and/or progression . The investigator already perform phase I safety study leukemia patient complete remission demonstrate absence side effect feasibility therapy . Here , investigator want extend strategy study clinical efficacy autologous DC vaccination patient acute chronic myeloid leukemia myeloma patient . Effects DC therapy immune reactivity towards leukemia cell well clinical parameter molecular MRD monitoring , time relapse ( TTR ) , progression-free survival ( PFS ) overall survival ( OS ) study vaccinate non-vaccinated ( control ) patient . Patients vaccinate use dendritic cell electroporated mRNA cod full-length Wilms ' tumor antigen WT1 .</brief_summary>
	<brief_title>Efficacy Dendritic Cell Therapy Myeloid Leukemia Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Acute Myeloid Leukemia ( AML ) : FAB subtypes except M3 . Extent disease : clinical remission least one course polychemotherapy high risk relapse due age ( &gt; 60 year ) poor risk cytogenetic/molecular marker hyperleukocytosis presentation previous relapse Chronic myeloid leukemia ( CML ) : patient chronic phase therapy tyrosinase kinase inhibitor suboptimal response failure eligible hematopoietic stem cell transplantation . Multiple Myeloma ( MM ) : symptomatic active disease , independent early and/or concomitant treatment : Presence serum/urine M protein ( &gt; 3 g/dl ) Bone marrow plasmacytosis ( &gt; 1030 % ) Anemia , renal failure , hypercalcemia , and/or lytic bone lesion Overexpression WT1 RNA peripheral blood bone marrow assess quantitative RTPCR time presentation.For CML : residual molecular disease demonstrate BCRABL RTPCR Prior treatment : Patients must receive least one prior antileukemic chemotherapeutic regimen must 1 month past last treatment . Age : ≥ 18 year Performance status : WHO PS grade 01 ( Appendix B ) Objectively assessable parameter life expectancy : 3 month Prior concomitant associate disease allow exception underlie autoimmune disease positive serology HIV/HBV/HCV No concomitant use immunosuppressive drug adequate renal liver function , i.e . creatinin bilirubin = 1.2 time upper limit normal absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Women childbearing potential use adequate contraception prior study entry duration study participation Subjects concurrent additional malignancy ( exception nonmelanoma skin cancer carcinoma situ cervix ) Subjects pregnant Subjects sensitivity drug provide local anesthesia Subjects needing corticosteroid 1 mg/kg vaccination ; corticosteroid allow part treatment take ≥ 30 day start vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>AML ( acute myeloid leukemia )</keyword>
	<keyword>CML ( chronic myeloid leukemia )</keyword>
	<keyword>MM ( multiple myeloma )</keyword>
</DOC>